José A. Fontenla - Concepedia

Author

José A. Fontenla

Universidade de Santiago de Compostela ORCID

Also Known As

Calleja, José, J A Fontenla, J FONTENLA, J. A. FONTENLA, J. A. Fontenla, J.A Fontenla, J.A. Fontenla, J.‐A. FONTENLA, Jose A. FONTENLA, Jose A. Fontenla

Publications

716

Citations

H-Index

Concepts

All Affiliations

Universidade de Santiago de Compostela Instituto Cajal Columbia University Irving Medical Center Center for Research in Molecular Medicine and Chronic Diseases Universidade do Porto

About

José A. Fontenla is an author at Universidade de Santiago de Compostela specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	334
2	Pharmacology	10	11	334
3	Natural Sciences	8	8	239
4	Biochemistry	8	8	262
5	Chemistry	2	2	26

José A. Fontenla

Publications

634

Citations

H-Index

Page 1

	Year	Citations
Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents C. FERNANDEZ, Ofelia Nieto, Emilia Rivas, Carbohydrate Research Medicinal ChemistryGlycosyl Dopamine DerivativesBiochemistryFunctional SelectivityMedicine	2000	73
Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier GLUT-1Electronic supplementary information (ESI) available: experimental details for the preparation of all derivatives and biological assays. See http://www.rsc.org/suppdata/ob/b2/b212066f/ C. FERNANDEZ, Ofelia Nieto, José A. Fontenla, Organic & Biomolecular Chemistry	2003	71
Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: Synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study María João Matos, Santiago Vilar, Rosa Ma Gonzalez-Franco, European Journal of Medicinal Chemistry Medicinal ChemistryBiochemistryMedicineNatural SciencesAdme Properties	2013	60
Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson’s disease therapy Fernanda Rodríguez‐Enríquez, María Carmen Costas-Lago, Pedro Besada, Bioorganic Chemistry Molecular PharmacologyMedicinePsychotropic MedicationNeuropharmacologySelective Mao-b Inhibitors	2020	51
Neuropharmacological effects of the ethanolic extract of Sida acuta Dora Benjumea, Isabel Gómez-Betancur, Julieta Vásquez, Revista Brasileira de Farmacognosia	2016	35
New arylpiperazine derivatives with high affinity for α1A, D2 and 5-HT2A receptors José C. González‐Gómez, Lourdes Santana, Eugenio Uriarte, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyBiochemistry5-Ht2a ReceptorsNew Arylpiperazine DerivativesMedicine	2003	34
Synthesis and Atypical Antipsychotic Profile of Some 2-(2-Piperidinoethyl)benzocycloalkanones as Analogs of Butyrophenone José A. Fontenla, J. I. Osuna, Elizabeth De La Rosa, Journal of Medicinal Chemistry	1994	33
Conformationally Constrained Butyrophenones with Mixed Dopaminergic (D<sub>2</sub>) and Serotoninergic (5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>) Affinities: Synthesis, Pharmacology, 3D-QSAR, and Molecular Modeling of (Aminoalkyl)benzo- and -thienocycloalkanones as Putative Atypical Antipsychotics Enrique Raviña, Jesús Negreira, José M. Cid, Journal of Medicinal Chemistry	1999	32
Pyridazine Derivatives. XI: Antihypertensive Activity of 3-Hydrazinocycloheptyl[1,2-c]pyridazine and Its Hydrazone Derivatives José Gil‐Longo, Reyes Laguna, Ignácio Verde, Journal of Pharmaceutical Sciences Medicinal ChemistryHydrazone DerivativesDerivativesDerivative (Chemistry)Biochemistry	1993	32
Synthesis, Pharmacological Study and Docking Calculations of New Benzo[ <i>f</i> ]coumarin Derivatives as Dual Inhibitors of Enzymatic Systems Involved in Neurodegenerative Diseases María João Matos, Patricia Janeiro, Rosa María González Franco, Future Medicinal Chemistry	2014	29

Page 1